1. Show article details.

    BRIEF-Charles River Laboratories Announces Q2 Revenue Of $682.6 Mln

    Reuters – 7:47 AM ET 08/05/2020


  2. Show article details.

    Charles River Laboratories Announces Second-Quarter 2020 Results

    Business Wire – 7:00 AM ET 08/05/2020

    – Second-Quarter Revenue of $682.6 Million – – Second-Quarter GAAP Earnings per Share of $1.34 and Non-GAAP Earnings per Share of $1.58 – – Increases 2020 Guidance – – Announces Proposed Acquisition of Cellero in the High-Growth Cell Therapy Market – WILMINGTON, Mass. Acquisitions contributed 3.2% to consolidated second-quarter revenue growth.

  3. Show article details.

    Charles River Laboratories Schedules Second-Quarter 2020 Earnings Release and Conference Call

    Business Wire – 8:30 AM ET 07/14/2020

    Charles River Laboratories International, Inc. (CRL) will release second-quarter 2020 financial results on Wednesday, August 5th, before the market opens. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website.

  4. Show article details.

    Dr. Carl Craig Has Been Promoted to CEO for Both Agricor Laboratories and Botanacor Laboratories. Dr. Craig Had Been the Companies’ COO.

    Business Wire – 3:10 PM ET 07/06/2020

    For Over Thirty Years Dr. Craig Has Served in Senior Leadership Roles at Microbial, Environmental, and Life Science Labs. Agricor Laboratories and Botanacor Laboratories jointly announced that Carl Craig has assumed the role of CEO of both companies. Agricor Laboratories is widely known as Colorado’s premier state-certified marijuana testing laboratory.

  5. Show article details.

    HemaCare Adds GMPrimeTM Cryopreserved Leukopak to its GMP Product Portfolio

    Business Wire – 8:00 AM ET 06/02/2020

    Simplify complex study logistics with GMP-compliant cryopreserved leukopak for the development and commercialization of cell and gene therapies.

  6. Show article details.

    Wildlife groups pressure Big Pharma to curb crab blood addiction

    Reuters – 2:55 PM ET 06/01/2020

    * Groups urge drugmakers to drop crab blood, adopt synthetic. * U.S. standards group says more data needed on man-made version. * Eli Lilly (LLY) switched to synthetic, urges others to follow. By John Miller.

  7. Show article details.

    Charles River Laboratories to Participate in Jefferies and William Blair Conferences

    Business Wire – 8:00 AM ET 06/01/2020

    Charles River Laboratories International, Inc. (CRL) announced today that it will virtually present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2nd, at 10:00 a.m. ET, and at the William Blair 40th Annual Growth Stock Conference on Tuesday, June 9th, at 10:00 a.m. CT. Management will present an overview of Charles River’s strategic focus and business developments.

  8. Show article details.

    Drugs standards group nixes plan to kick pharma's crab blood habit

    Reuters – 11:42 AM ET 05/30/2020

    Horseshoe crabs' icy-blue blood is set to remain the drug industry's standard for safety tests after a powerful U.S. group ditched a plan to put on an equal footing a synthetic substitute pushed by Swiss biotech Lonza and animal welfare groups. The crabs' copper-rich blood clots in the presence of bacterial endotoxins and has long been used in tests to detect contamination in shots and infusions.


Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Aug

    CRL announced Q2 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

See the Latest Features
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.